查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924500

尿石素B市場按用途、形態、來源、通路、最終用戶和等級分類－2026-2032年全球預測

Urolithin B Market by Application, Form, Source, Distribution Channel, End User, Grade - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年尿石素 B 市值為 7.7822 億美元，預計到 2026 年將成長至 8.5441 億美元，預計到 2032 年將達到 16.0369 億美元，複合年成長率為 10.88%。

關鍵市場統計數據
基準年 2025 7.7822億美元
預計年份：2026年 8.5441億美元
預測年份 2032 1,603,690,000 美元
複合年成長率 (%) 10.88%

對尿石素B的科學起源、生產途徑和商業化策略考量進行了簡明扼要且權威全面的說明

尿石素B的出現源自於腸道微生物組科學與功能性成分創新的融合，它已成為配方師、臨床醫生和原料生產商極為關注的生物活性化合物。該化合物由腸道微生物代謝膳食來源的鞣花單寧在體內產生，也可透過可控制生物發酵或合成途徑取得。尿石素B因其支持粒線體功能、抗發炎活性和增強肌肉性能等潛在特性而備受矚目。分析化學的進步、可重複的生產技術以及不斷擴展的轉化研究，已使尿石素B從實驗室中的奇特化合物發展成為具有多種潛在商業應用的領先候選藥物。

技術成熟度、監管審查和不斷變化的消費者偏好如何共同作用，重塑尿石素B商業化的機會和障礙

受技術、監管和消費者主導等多面向因素的影響，尿石素B的市場格局正在快速變化，其商業化路徑也隨之重塑。精準生物發酵技術的進步降低了產品變異性，並提高了產量穩定性，使供應商能夠提供雜質譜更窄、功能效果更可預測的產品。同時，合成化學的進步正在創造可擴展的替代方案，以滿足生物來源原料供應緊張情況下的需求，從而支持供應多元化和單位成本最佳化。

評估2025年美國關稅變化對尿石素B供應鏈韌性、籌資策略和在地化生產的策略影響

2025年新關稅的實施為尿石素B相關相關人員帶來了複雜的供應鏈、採購和定價挑戰。由於這種生物活性物質的生產過程可能依賴進口前體、專用發酵設備或契約製造關係，進口關稅的分階段實施將直接影響最終到岸成本以及國內與海外生產決策。為此，一些供應商正在加快對本地生物發酵能力和分析實驗室的投資，以降低跨境價格波動風險。

策略性細分分析能夠深入洞察用途、劑型、來源、通路、最終用戶和等級選擇如何決定配方開發路徑和商業化策略。

細分市場層面的趨勢能夠最有效地洞察尿石素B在相關產業和產品結構中的應用前景。應用細分決定了配方和監管方面的優先事項：在化妝品和個人護理領域，穩定性、局部安全性和與現有載體系統的相容性是關鍵需求；在營養保健品領域，口服生物有效性以及易於包封和壓片至關重要；在機能性食品和飲料領域，必須考慮掩味、溶解性和熱穩定性；在製藥領域，最高純度和可控的臨床路徑必不可少和可控的臨床路徑。

區域戰略考量：美洲、歐洲、中東和非洲以及亞太地區的趨勢將如何影響生產、研發重點和商業化優先事項。

區域趨勢將決定在生產、臨床研究和商業性夥伴關係的投資在哪些地區能夠獲得最大回報。在美洲，對經臨床驗證的營養保健品和功能性成分的需求正推動著運動營養品和膳食補充劑生產商的濃厚興趣。這得益於當地強大的臨床研究文化以及消費者願意為差異化的生物活性成分買單。這種環境促使供應商優先進行人體干預研究，並最佳化符合消費者習慣的產品形式，例如膠囊和粉末。

構成尿石素B生態系統的原料開發商、契約製造和商業夥伴的企業策略和競爭策略

尿石素B價值鏈上的企業正採取多種策略來確保競爭優勢，從專有的培養技術平台到整合臨床數據和分銷能力的合作關係，不一而足。創新者正投資於上游工程開發，以降低變異性，透過一致的雜質譜實現差異化，並提高穩定性。作為回應，契約製造製造商和原料供應商正在擴展其分析能力，以提供符合化妝品、食品和藥品標準的多種等級的認證批次產品。

為確保尿石素B的供應穩定、獲得監管機構批准和市場差異化，製造商、配方師和商業團隊可採取切實可行的優先行動。

我們鼓勵業界領導者採取多元化、風險管理的策略，以掌握尿石素B帶來的機會。首先，應優先投資於品質和原料可追溯性，具體措施包括擴展分析基礎設施，並對生物發酵和合成來源合格。這將確保業務永續營運，並支持針對不同等級尿石素B的擴張。這種方法將減少對單一來源的依賴，並支援根據客戶需求的變化，在化妝品、食品、藥品和標準等級之間快速切換。

一種透明、多方面的調查方法，結合了深度訪談、實驗室檢驗、監管分析和供應鏈分析，為策略建議提供支援。

為確保研究結果的穩健性和相關性，本研究採用了多種互補的方法。一級資訊來源包括對原料研發人員、契約製造、法規顧問和製劑研發人員的結構化訪談，以了解他們的實踐和商業性意圖。二級資訊來源包括對同儕審查文獻、臨床試驗註冊庫、專利申請和監管公告的系統性回顧，以檢驗作用機制、安全性概況和申報資料要求。這些資訊來源的整合使我們能夠從多層次理解科學檢驗、智慧財產權趨勢和合規標準。

成功擴大尿石素B解決方案規模的關鍵在於科學、製造和商業性要素的整合。

尿石素B正處於科學檢驗、生產成熟度和商業性需求交會的關鍵節點，由此衍生出多種價值創造路徑。該成分的未來將取決於相關人員能否證明其具有可重複的生物學效應，能否確保建立穩健且分級的供應鏈，以及能否使產品形態和功效宣稱與特定管道的預期相符。隨著證據基礎的不斷擴展和生產方式的增多，那些能夠平衡臨床投入、營運嚴謹性和本地市場敏感性的公司，將更有能力將潛力轉化為持續的商業性成功。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依應用分類的尿石素B市場

  • 化妝品和個人護理
  • 營養補充品
  • 機能性食品和飲料
  • 製藥

9. 尿石素B市場依形式分類

  • 膠囊
  • 液體
  • 粉末
  • 藥片

第10章 尿石素B市場（依來源分類）

  • 生物發酵
  • 合成

第11章 尿石素B市場（依分銷管道分類）

  • 直銷
  • 線上
  • 專賣店

第12章 尿石素B市場（依最終用戶分類）

  • 化妝品製造商
  • 營養補充品製造商
  • 製藥公司
  • 研究所

第13章 尿石素B 市場依等級分類

  • 化妝品級
  • 食品級
  • 醫藥級
  • 標準級

第14章 各地區尿石素B市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 尿石素B市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國尿石素B市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國尿石素B市場

第18章 中國尿石素B市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bio-Botanica Inc.
  • Cayman Chemical Company
  • Hangzhou Ark Biotechnology Co., Ltd.
  • Indena SpA
  • International Flavors & Fragrances Inc.
  • Merck KGaA
  • Nutraveris SAS
  • PLT Health Solutions Ltd.
  • Sabinsa Corporation
  • Toronto Research Chemicals Inc.
Product Code: MRR-7A380DA7C358

The Urolithin B Market was valued at USD 778.22 million in 2025 and is projected to grow to USD 854.41 million in 2026, with a CAGR of 10.88%, reaching USD 1,603.69 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 778.22 million
Estimated Year [2026] USD 854.41 million
Forecast Year [2032] USD 1,603.69 million
CAGR (%) 10.88%

A concise, authoritative synthesis of Urolithin B's scientific origins, manufacturing pathways, and strategic considerations for commercial translation

Urolithin B has emerged from the confluence of gut microbiome science and functional ingredient innovation to become a high-interest bioactive for formulators, clinicians, and ingredient manufacturers. Derived in vivo from dietary ellagitannins through microbial metabolism and available via controlled biofermentation or synthetic routes, this compound has attracted attention for its putative mitochondrial-supportive, anti-inflammatory, and muscle-performance properties. The convergence of improved analytical chemistry, reproducible manufacturing techniques, and an expanding body of translational research has moved Urolithin B from laboratory curiosity into a credible candidate for multiple commercial applications.

In practice, the development pathway for Urolithin B demands a multidisciplinary approach that balances rigorous clinical evidence, regulatory navigation, and manufacturing quality. Regulatory clarity and grade differentiation shape how the ingredient can be deployed across cosmetic, food, and pharmaceutical contexts, while advances in formulation science enable incorporation into capsules, liquids, powders, and tablets with predictable stability and bioavailability profiles. Given these dynamics, stakeholders-ranging from ingredient innovators and contract manufacturers to R&D teams within consumer brands-need a precise synthesis of scientific provenance, supply chain realities, and commercial use cases to prioritize investments and mitigate downstream risk.

Taken together, the introduction of Urolithin B into product pipelines reflects a broader shift in how novel bioactives are validated and commercialized: emphasis on mechanism-backed claims, scalable and reproducible supply, and segmentation-specific grade control to meet regulatory and safety standards. For strategic decision-makers, understanding these foundational elements is the precursor to building differentiated products that satisfy both regulatory scrutiny and consumer expectations.

How technological maturation, regulatory scrutiny, and evolving consumer preferences are converging to reshape opportunities and barriers for Urolithin B commercialization

The landscape for Urolithin B is shifting rapidly under the influence of technological, regulatory, and consumer-driven forces that are reshaping commercialization pathways. Advances in precision biofermentation have reduced variability and increased yield consistency, enabling suppliers to offer product forms with narrower impurity profiles and more predictable functional outcomes. At the same time, improvements in synthetic chemistry have produced scalable alternatives that can meet demand when biological feedstocks are constrained, supporting diversification of supply and unit-cost optimization.

Regulatory trajectories are also evolving; authorities are increasingly scrutinizing provenance, impurity profiles, and clinical substantiation for novel bioactives. This scrutiny is prompting companies to invest in robust toxicology packages and human intervention studies that can support differentiated claims for specific use cases. Concurrently, consumers are shifting their preferences toward scientifically substantiated, transparent ingredients and away from generalized wellness assertions. This trend encourages brands to prioritize clinical endpoints and to partner with research institutions to build credibility.

On the commercialization front, distribution and engagement models are transforming. Direct-to-consumer pathways and enhanced online specialty channels allow targeted product launches and rapid consumer feedback loops, while traditional contract sales and specialty retail remain important for institutional buyers and professional channels. Formulation advances-particularly for oral delivery systems-support the creation of multiple product types, expanding route-to-market options. These cumulative shifts underscore that success in the Urolithin B ecosystem requires simultaneous investments in manufacturing fidelity, clinical evidence, regulatory strategy, and channel-specific go-to-market planning.

Assessing the strategic consequences of the 2025 United States tariff changes on supply chain resilience, sourcing strategies, and manufacturing localization for Urolithin B

The implementation of new tariffs in 2025 has introduced a complex layer of supply chain, sourcing, and pricing considerations for stakeholders involved with Urolithin B. Because manufacturing pathways for this bioactive can rely on imported precursors, specialized fermentation equipment, or contract manufacturing relationships, incremental import duties have immediate implications for landed cost and for decisions about domestic versus offshore production. In response, some suppliers have accelerated investments in local biofermentation capacity and analytical laboratories to reduce exposure to cross-border volatility.

Moreover, tariffs have influenced procurement strategies across the value chain. Ingredient buyers in formulations have begun negotiating longer-term supply agreements and exploring dual-sourcing strategies that combine biofermented and synthetic options to preserve continuity if one pathway becomes economically disadvantaged. This rebalancing has ripple effects: contract manufacturers are reviewing master production schedules, cosmetic and supplement companies are re-evaluating price positioning, and specialty distributors are adjusting inventory holdings to manage margin compression.

At the same time, tariffs have incentivized certain firms to pursue greater vertical integration, absorbing portions of the upstream supply chain to capture margin and ensure quality controls. Importantly, these adjustments have not only economic consequences but also strategic ones: tighter control over manufacturing enables faster responses to regulatory requests for batch-level traceability and supports the generation of pharma-grade dossiers where needed. Looking forward, the cumulative impact of tariffs will likely remain a durable factor influencing capital allocation, partnership models, and the geographic distribution of production facilities across the broader Urolithin B ecosystem.

Strategic segmentation insights detailing how application, form, source, distribution channel, end-user, and grade choices determine formulation pathways and commercialization strategies

Segment-level dynamics provide the most actionable view of how Urolithin B will be adopted across adjacent industries and product architectures. Application segmentation drives formulation and regulatory priorities: in cosmetics and personal care contexts, demand centers on stability, topical safety, and compatibility with existing carrier systems; within dietary supplements, oral bioavailability and straightforward encapsulation or tableting are paramount; functional foods and beverages require taste-masking, solubility, and thermal stability considerations; and pharmaceutical uses necessitate the highest purity and controlled clinical development pathways.

Form considerations directly affect manufacturing and go-to-market choices. Capsule, liquid, powder, and tablet presentations each impose different constraints on excipients, stability testing, and packaging systems. For example, powders may be preferred where blend uniformity and controlled dosing are priorities, while liquids can accelerate direct-to-consumer product launches but demand preservative and stability strategies. The source of the ingredient-whether biofermented or synthetic-further shapes positioning, with biofermented supply often carrying consumer-facing narratives about natural origin and microbiome relevance, while synthetic routes can offer cost consistency and scalable supply that suits industrial-scale pharmaceutical or bulk supplement production.

Distribution channel segmentation influences commercialization cadence and customer engagement models. Direct sales and specialty store placements typically require deeper technical support and longer lead times to establish relationships with cosmetic manufacturers, dietary supplement manufacturers, and pharmaceutical companies. Conversely, online channels can accelerate consumer adoption but necessitate clear claims and robust quality assurances to withstand regulatory and consumer scrutiny. End-user segmentation also highlights divergent buyer needs: cosmetic manufacturers prioritize formulation compatibility and cosmetic grade specifications, dietary supplement manufacturers seek food grade or standard grade material with supply continuity, pharmaceutical companies demand pharmaceutical grade sourcing and full regulatory documentation, and research institutions often require small-batch, high-purity material for mechanistic studies.

Finally, grade differentiation-cosmetic grade, food grade, pharmaceutical grade, and standard grade-serves as a critical gating factor for pricing, certification, and allowable claims. Manufacturers and brands must align grade selection with intended use cases, regulatory pathways, and target channels to avoid product redeployment risks and to optimize time-to-market for each segment.

Regional strategic considerations explaining how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics influence production, research focus, and commercialization priorities

Regional dynamics will determine where investments in production, clinical research, and commercial partnerships yield the greatest return. In the Americas, demand for clinically substantiated nutraceuticals and performance ingredients drives interest from sports nutrition and dietary supplement manufacturers, supported by a strong culture of clinical research and consumer willingness to pay for differentiated bioactives. This environment encourages suppliers to prioritize human intervention studies and to optimize forms that align with consumer habits, such as capsules and powders.

Europe, Middle East & Africa exhibits a fragmented regulatory landscape and divergent consumer expectations that together shape entry strategies. Certain European markets emphasize natural origin and sustainability credentials, favoring biofermented supply chains and transparent sourcing narratives, while regulatory rigor in several jurisdictions requires substantive safety dossiers for novel ingredients. Middle Eastern and African markets are uneven in regulatory development but present channels for premium cosmetic deployments and specialty formulations, particularly when supported by localized partnerships and certification frameworks.

Asia-Pacific continues to be a dual-engine region: it hosts significant manufacturing scale and a vibrant R&D ecosystem capable of advancing both biofermentation and synthetic production routes, while burgeoning consumer demand for beauty-from-within and performance wellness products fuels commercial adoption. Cross-border trade, regional manufacturing clusters, and cost-competitive production make Asia-Pacific a strategically important place for both pilot manufacturing and larger-scale supply. Across regions, alignment between supply source, grade, and local regulatory expectations will determine the speed and scope of market entry, and companies that tailor their approach regionally will better mitigate compliance risk and accelerate adoption.

Corporate strategies and competitive plays from ingredient innovators, contract manufacturers, and commercial partners that are shaping the Urolithin B ecosystem

Companies active in the Urolithin B value chain are pursuing a range of strategic plays to secure competitive advantage, from proprietary fermentation platforms to partnerships that bundle clinical data with distribution strength. Innovators are investing in upstream process development to reduce variation and to support differentiation through consistent impurity profiles and enhanced stability. Contract manufacturers and ingredient houses are responding by expanding analytic capabilities, offering certified batches at multiple grades to satisfy cosmetic, food, and pharmaceutical specifications.

On the commercialization side, firms are prioritizing clinical validation and IP protection. Clinical programs focused on muscle function, mitochondrial biomarkers, and systemic anti-inflammatory endpoints help position ingredients for premium placement in supplements and for supportive claims in cosmetic formulations. Simultaneously, companies are using licensing arrangements and co-development partnerships with cosmetic manufacturers, dietary supplement manufacturers, and pharmaceutical companies to accelerate product launches and to de-risk market access. Strategic M&A activity and selective vertical integration are other recurring themes as firms seek to lock in supply, ensure quality, and capture greater share of downstream margin.

Finally, nimble players are leveraging distribution sophistication-combining direct sales relationships with online specialty retail strategies-to test consumer messaging, collect real-world evidence, and iterate formulations quickly. This blended approach allows commercial leaders to refine positioning in a data-driven manner while protecting premium channel relationships that require longer lead times and stronger technical support.

Practical, prioritized actions for manufacturers, formulators, and commercial teams to secure supply resilience, regulatory clearance, and market differentiation for Urolithin B

Industry leaders should adopt a multi-pronged, risk-managed strategy to capture value in the Urolithin B opportunity. First, prioritize investments in quality and provenance by expanding analytical infrastructure and by qualifying both biofermented and synthetic supply streams to ensure business continuity and to enable grade-specific deployments. This approach reduces dependence on single-source suppliers and supports rapid shifts between cosmetic grade, food grade, pharmaceutical grade, and standard grade as customer needs evolve.

Second, accelerate clinical and translational research aligned to target applications. Sponsors should focus on indication-relevant endpoints that resonate with cosmetic manufacturers, dietary supplement manufacturers, and pharmaceutical companies, thereby creating evidence packages that support differentiated claims and premium positioning. Early engagement with regulatory stakeholders and third-party certifiers will further streamline market entry and reduce time-to-shelf.

Third, diversify go-to-market channels by pairing traditional direct sales and specialty store strategies with targeted online launches. This combination enables rapid consumer testing and feedback while preserving institutional relationships that require deeper technical dialogue. Additionally, pursue strategic partnerships and licensing agreements that bundle clinical data with co-development commitments to de-risk commercialization and accelerate revenue generation.

Finally, develop regional playbooks that reflect local regulatory nuances, consumer preferences, and manufacturing capacities. Allocate capital toward manufacturing localization where tariffs or logistics impose persistent cost penalties, and invest in local R&D collaborations to tailor formulations for specific markets. Taken together, these actions position companies to convert scientific promise into sustainable commercial advantage.

A transparent, multi-method research approach combining primary interviews, laboratory verification, regulatory analysis, and supply chain mapping to underpin strategic recommendations

The research behind these insights integrates multiple complementary methods to ensure robustness and relevance. Primary inputs included structured interviews with ingredient developers, contract manufacturers, regulatory consultants, and formulators to capture operational realities and commercial intent. Secondary inputs involved a systematic review of peer-reviewed literature, clinical trial registries, patent filings, and regulatory notices to validate mechanisms of action, safety profiles, and dossier expectations. Together, these sources provided a layered understanding of scientific validation, intellectual property dynamics, and compliance standards.

Analytical verification was conducted using standardized laboratory profiling to confirm identity, assay, and impurity characterization across representative batches from both biofermented and synthetic sources. Supply chain mapping exercises traced raw material dependencies, production bottlenecks, and logistics constraints to identify points of fragility, while scenario modeling evaluated the operational implications of tariff changes and sourcing disruptions. Finally, a cross-sectional segmentation analysis aligned product forms and grades with end-user requirements to surface practical commercialization pathways.

This blended methodology-combining qualitative stakeholder input, quantitative laboratory verification, and strategic supply chain analysis-ensures that recommendations are grounded in both empirical evidence and real-world commercial dynamics. Transparency in methods and reproducibility of key tests were prioritized to allow clients to validate findings and to apply the insights to their specific decision frameworks.

A decisive synthesis of the scientific, manufacturing, and commercial imperatives that will determine which organizations successfully scale Urolithin B solutions

Urolithin B stands at a pivotal juncture where scientific validation, manufacturing maturity, and commercial demand intersect to create diverse pathways for value creation. The ingredient's trajectory will be shaped by the ability of stakeholders to demonstrate reproducible biological effects, to secure resilient and graded supply chains, and to align product form and claims with channel-specific expectations. As the evidence base grows and manufacturing options proliferate, companies that balance clinical investment with operational rigor and regional market sensitivity will be best positioned to translate potential into sustained commercial success.

In conclusion, the opportunity for Urolithin B extends beyond single-market launches: it requires an orchestrated strategy that integrates grade selection, source diversification, regulatory preparation, and channel-specific commercialization. Decision-makers should treat this moment as an inflection point to solidify partnerships, invest in quality systems, and accelerate targeted evidence generation. By doing so, organizations can minimize risk, capture premium positioning, and scale responsibly as the ingredient moves toward broader adoption across cosmetics, supplements, functional foods, and pharmaceutical applications.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Urolithin B Market, by Application

  • 8.1. Cosmetics & Personal Care
  • 8.2. Dietary Supplements
  • 8.3. Functional Foods & Beverages
  • 8.4. Pharmaceuticals

9. Urolithin B Market, by Form

  • 9.1. Capsule
  • 9.2. Liquid
  • 9.3. Powder
  • 9.4. Tablet

10. Urolithin B Market, by Source

  • 10.1. Biofermented
  • 10.2. Synthetic

11. Urolithin B Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Online
  • 11.3. Specialty Stores

12. Urolithin B Market, by End User

  • 12.1. Cosmetic Manufacturers
  • 12.2. Dietary Supplement Manufacturers
  • 12.3. Pharmaceutical Companies
  • 12.4. Research Institutions

13. Urolithin B Market, by Grade

  • 13.1. Cosmetic Grade
  • 13.2. Food Grade
  • 13.3. Pharmaceutical Grade
  • 13.4. Standard Grade

14. Urolithin B Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Urolithin B Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Urolithin B Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Urolithin B Market

18. China Urolithin B Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Bio-Botanica Inc.
  • 19.6. Cayman Chemical Company
  • 19.7. Hangzhou Ark Biotechnology Co., Ltd.
  • 19.8. Indena S.p.A.
  • 19.9. International Flavors & Fragrances Inc.
  • 19.10. Merck KGaA
  • 19.11. Nutraveris SAS
  • 19.12. PLT Health Solutions Ltd.
  • 19.13. Sabinsa Corporation
  • 19.14. Toronto Research Chemicals Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL UROLITHIN B MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL UROLITHIN B MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL UROLITHIN B MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL UROLITHIN B MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL UROLITHIN B MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL UROLITHIN B MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL UROLITHIN B MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL UROLITHIN B MARKET SIZE, BY GRADE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL UROLITHIN B MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL UROLITHIN B MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL UROLITHIN B MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES UROLITHIN B MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA UROLITHIN B MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL UROLITHIN B MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL UROLITHIN B MARKET SIZE, BY COSMETICS & PERSONAL CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL UROLITHIN B MARKET SIZE, BY COSMETICS & PERSONAL CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL UROLITHIN B MARKET SIZE, BY COSMETICS & PERSONAL CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL UROLITHIN B MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL UROLITHIN B MARKET SIZE, BY DIETARY SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL UROLITHIN B MARKET SIZE, BY DIETARY SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL UROLITHIN B MARKET SIZE, BY FUNCTIONAL FOODS & BEVERAGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL UROLITHIN B MARKET SIZE, BY FUNCTIONAL FOODS & BEVERAGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL UROLITHIN B MARKET SIZE, BY FUNCTIONAL FOODS & BEVERAGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL UROLITHIN B MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL UROLITHIN B MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL UROLITHIN B MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL UROLITHIN B MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL UROLITHIN B MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL UROLITHIN B MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL UROLITHIN B MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL UROLITHIN B MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL UROLITHIN B MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL UROLITHIN B MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL UROLITHIN B MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL UROLITHIN B MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL UROLITHIN B MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL UROLITHIN B MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL UROLITHIN B MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL UROLITHIN B MARKET SIZE, BY BIOFERMENTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL UROLITHIN B MARKET SIZE, BY BIOFERMENTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL UROLITHIN B MARKET SIZE, BY BIOFERMENTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL UROLITHIN B MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL UROLITHIN B MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL UROLITHIN B MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL UROLITHIN B MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL UROLITHIN B MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL UROLITHIN B MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL UROLITHIN B MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL UROLITHIN B MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL UROLITHIN B MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL UROLITHIN B MARKET SIZE, BY SPECIALTY STORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL UROLITHIN B MARKET SIZE, BY SPECIALTY STORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL UROLITHIN B MARKET SIZE, BY SPECIALTY STORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL UROLITHIN B MARKET SIZE, BY COSMETIC MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL UROLITHIN B MARKET SIZE, BY COSMETIC MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL UROLITHIN B MARKET SIZE, BY COSMETIC MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL UROLITHIN B MARKET SIZE, BY DIETARY SUPPLEMENT MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL UROLITHIN B MARKET SIZE, BY DIETARY SUPPLEMENT MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL UROLITHIN B MARKET SIZE, BY DIETARY SUPPLEMENT MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL UROLITHIN B MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL UROLITHIN B MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL UROLITHIN B MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL UROLITHIN B MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL UROLITHIN B MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL UROLITHIN B MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL UROLITHIN B MARKET SIZE, BY COSMETIC GRADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL UROLITHIN B MARKET SIZE, BY COSMETIC GRADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL UROLITHIN B MARKET SIZE, BY COSMETIC GRADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL UROLITHIN B MARKET SIZE, BY FOOD GRADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL UROLITHIN B MARKET SIZE, BY FOOD GRADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL UROLITHIN B MARKET SIZE, BY FOOD GRADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL UROLITHIN B MARKET SIZE, BY PHARMACEUTICAL GRADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL UROLITHIN B MARKET SIZE, BY PHARMACEUTICAL GRADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL UROLITHIN B MARKET SIZE, BY PHARMACEUTICAL GRADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL UROLITHIN B MARKET SIZE, BY STANDARD GRADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL UROLITHIN B MARKET SIZE, BY STANDARD GRADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL UROLITHIN B MARKET SIZE, BY STANDARD GRADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL UROLITHIN B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS UROLITHIN B MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA UROLITHIN B MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL UROLITHIN B MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 136. GCC UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GCC UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. GCC UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 139. GCC UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 140. GCC UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. GCC UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. GCC UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 157. G7 UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. G7 UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. G7 UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 160. G7 UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 161. G7 UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. G7 UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. G7 UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 164. NATO UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. NATO UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. NATO UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 167. NATO UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 168. NATO UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. NATO UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. NATO UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES UROLITHIN B MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA UROLITHIN B MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)